| Item Type | Name |
|
Concept
|
Acrylates
|
|
Concept
|
Adrenergic alpha-Agonists
|
|
Concept
|
Albumins
|
|
Concept
|
Adenosine
|
|
Concept
|
Angiotensin II
|
|
Concept
|
Adrenergic alpha-Antagonists
|
|
Concept
|
Aldosterone
|
|
Concept
|
Apolipoproteins
|
|
Concept
|
Adamantane
|
|
Concept
|
Cyclic AMP
|
|
Concept
|
Allopurinol
|
|
Concept
|
Aminobutyrates
|
|
Concept
|
Analgesics, Opioid
|
|
Concept
|
Biphenyl Compounds
|
|
Concept
|
Adrenergic beta-Antagonists
|
|
Concept
|
Mineralocorticoid Receptor Antagonists
|
|
Concept
|
Blood Proteins
|
|
Concept
|
Anticonvulsants
|
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Carbazoles
|
|
Concept
|
Analgesics
|
|
Concept
|
Androstenes
|
|
Concept
|
Angiotensin-Converting Enzyme Inhibitors
|
|
Concept
|
Angiotensinogen
|
|
Concept
|
Anticoagulants
|
|
Concept
|
Anti-Inflammatory Agents, Non-Steroidal
|
|
Concept
|
Antihypertensive Agents
|
|
Concept
|
Central Nervous System Stimulants
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Anti-Inflammatory Agents
|
|
Concept
|
Arginine Vasopressin
|
|
Concept
|
Base Sequence
|
|
Concept
|
Benzazepines
|
|
Concept
|
Benzimidazoles
|
|
Concept
|
Atenolol
|
|
Concept
|
Benzoates
|
|
Concept
|
Benzopyrans
|
|
Concept
|
Aspartate Aminotransferases
|
|
Concept
|
Aspirin
|
|
Concept
|
Dipeptides
|
|
Concept
|
Diuretics
|
|
Concept
|
Calcitriol
|
|
Concept
|
Autoantibodies
|
|
Concept
|
Blood Glucose
|
|
Concept
|
Drug Tolerance
|
|
Concept
|
Benzhydryl Compounds
|
|
Concept
|
Calcifediol
|
|
Concept
|
Carbamazepine
|
|
Concept
|
Ethanolamines
|
|
Concept
|
Chromans
|
|
Concept
|
Chlorthalidone
|
|
Concept
|
Free Radicals
|
|
Concept
|
C-Reactive Protein
|
|
Concept
|
Caffeine
|
|
Concept
|
Cardiotonic Agents
|
|
Concept
|
Creatinine
|
|
Concept
|
Cholesterol
|
|
Concept
|
Hemoglobins
|
|
Concept
|
Contrast Media
|
|
Concept
|
Amine Oxidase (Copper-Containing)
|
|
Concept
|
Hormones
|
|
Concept
|
Imidazoles
|
|
Concept
|
Drug Industry
|
|
Concept
|
Drug Synergism
|
|
Concept
|
Diatrizoate Meglumine
|
|
Concept
|
Dihydropyridines
|
|
Concept
|
Insulin
|
|
Concept
|
Drug Evaluation
|
|
Concept
|
Drug Therapy
|
|
Concept
|
Gout Suppressants
|
|
Concept
|
Labetalol
|
|
Concept
|
Enzyme Inhibitors
|
|
Concept
|
Estradiol
|
|
Concept
|
Clonidine
|
|
Concept
|
Erythropoietin
|
|
Concept
|
Digitalis Glycosides
|
|
Concept
|
DNA
|
|
Concept
|
Drug Utilization
|
|
Concept
|
Dipyridamole
|
|
Concept
|
Drug Resistance
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Fumarates
|
|
Concept
|
Fatty Acids, Nonesterified
|
|
Concept
|
Indoles
|
|
Concept
|
Egtazic Acid
|
|
Concept
|
Glucagon-Like Peptides
|
|
Concept
|
Mineralocorticoids
|
|
Concept
|
Fludrocortisone
|
|
Concept
|
Fluorouracil
|
|
Concept
|
Atrial Natriuretic Factor
|
|
Concept
|
Furosemide
|
|
Concept
|
Nifedipine
|
|
Concept
|
Diclofenac
|
|
Concept
|
Disopyramide
|
|
Concept
|
Glucosides
|
|
Concept
|
Hormone Antagonists
|
|
Concept
|
Dopamine
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Drug Combinations
|
|
Concept
|
Pharmaceutical Preparations
|
|
Concept
|
Hydralazine
|
|
Concept
|
Hypoglycemic Agents
|
|
Concept
|
Enalapril
|
|
Concept
|
Heptanoic Acids
|
|
Concept
|
Hydrochlorothiazide
|
|
Concept
|
Hydrocortisone
|
|
Concept
|
Hydroxyindoleacetic Acid
|
|
Concept
|
5-Hydroxytryptophan
|
|
Concept
|
Fertility Agents, Female
|
|
Concept
|
Isoenzymes
|
|
Concept
|
Gliclazide
|
|
Concept
|
Lactones
|
|
Concept
|
Lithium
|
|
Concept
|
Maleimides
|
|
Concept
|
Peptidyl-Dipeptidase A
|
|
Concept
|
Meglumine
|
|
Concept
|
Membrane Proteins
|
|
Concept
|
Metformin
|
|
Concept
|
Gonadotropin-Releasing Hormone
|
|
Concept
|
Lipids
|
|
Concept
|
Naltrexone
|
|
Concept
|
Metoprolol
|
|
Concept
|
Indazoles
|
|
Concept
|
Oxadiazoles
|
|
Concept
|
Receptors, Angiotensin
|
|
Concept
|
Mitogens
|
|
Concept
|
Peptide Fragments
|
|
Concept
|
Ion Channels
|
|
Concept
|
Iothalamic Acid
|
|
Concept
|
Nitric Oxide
|
|
Concept
|
Nitriles
|
|
Concept
|
Phosphorus
|
|
Concept
|
Organic Chemicals
|
|
Concept
|
Orphenadrine
|
|
Concept
|
Cholesterol, HDL
|
|
Concept
|
Safety
|
|
Concept
|
Parathyroid Hormone
|
|
Concept
|
Phenylurea Compounds
|
|
Concept
|
Oxygen
|
|
Concept
|
Polymers
|
|
Concept
|
Sympatholytics
|
|
Concept
|
Potassium
|
|
Concept
|
Drug Prescriptions
|
|
Concept
|
Fenofibrate
|
|
Concept
|
Tobramycin
|
|
Concept
|
Prostaglandins
|
|
Concept
|
Pyridoxamine
|
|
Concept
|
Pyrazines
|
|
Concept
|
Pyridines
|
|
Concept
|
Glyburide
|
|
Concept
|
Indapamide
|
|
Concept
|
Receptors, Purinergic
|
|
Concept
|
Reference Standards
|
|
Concept
|
Polystyrenes
|
|
Concept
|
Prostaglandin-Endoperoxide Synthases
|
|
Concept
|
Verapamil
|
|
Concept
|
Purines
|
|
Concept
|
Pyrrolidines
|
|
Concept
|
Quinolines
|
|
Concept
|
von Willebrand Factor
|
|
Concept
|
Xanthine Oxidase
|
|
Concept
|
Drugs, Investigational
|
|
Concept
|
Sodium
|
|
Concept
|
Serotonin
|
|
Concept
|
RNA
|
|
Concept
|
Sulfonylurea Compounds
|
|
Concept
|
Ibuprofen
|
|
Concept
|
Transferases
|
|
Concept
|
Tetrazoles
|
|
Concept
|
Superoxides
|
|
Concept
|
Sodium, Dietary
|
|
Concept
|
United States Food and Drug Administration
|
|
Concept
|
Superoxide Dismutase
|
|
Concept
|
Triglycerides
|
|
Concept
|
Lipoprotein(a)
|
|
Concept
|
Thiophenes
|
|
Concept
|
Vasodilator Agents
|
|
Concept
|
Xanthine Dehydrogenase
|
|
Concept
|
Silicates
|
|
Concept
|
Uric Acid
|
|
Concept
|
Dopamine Agents
|
|
Concept
|
Neprilysin
|
|
Concept
|
Levorphanol
|
|
Concept
|
Cholesterol, LDL
|
|
Concept
|
Intramolecular Oxidoreductases
|
|
Concept
|
Valine
|
|
Concept
|
Vasopressins
|
|
Concept
|
Transforming Growth Factor beta
|
|
Concept
|
Felodipine
|
|
Concept
|
Cell Adhesion Molecules
|
|
Concept
|
Lithium Carbonate
|
|
Concept
|
Culture Media, Conditioned
|
|
Concept
|
Glycation End Products, Advanced
|
|
Concept
|
Guanfacine
|
|
Concept
|
Drugs, Generic
|
|
Concept
|
Galectin 3
|
|
Concept
|
Receptors, Endothelin
|
|
Concept
|
Midodrine
|
|
Concept
|
Mucoproteins
|
|
Concept
|
Naproxen
|
|
Concept
|
Bupropion
|
|
Concept
|
Potassium, Dietary
|
|
Concept
|
Cyclooxygenase Inhibitors
|
|
Concept
|
Bisoprolol
|
|
Concept
|
Amlodipine
|
|
Concept
|
Lisinopril
|
|
Concept
|
Simvastatin
|
|
Concept
|
Cyclooxygenase 2 Inhibitors
|
|
Concept
|
Natriuretic Peptide, Brain
|
|
Concept
|
G-Protein-Coupled Receptor Kinase 4
|
|
Concept
|
Drug Dosage Calculations
|
|
Concept
|
Isradipine
|
|
Concept
|
Doxazosin
|
|
Concept
|
Reactive Oxygen Species
|
|
Concept
|
Receptors, Dopamine D1
|
|
Concept
|
Endosomal Sorting Complexes Required for Transport
|
|
Concept
|
Calcium Channels, T-Type
|
|
Concept
|
Sodium Chloride, Dietary
|
|
Concept
|
PPAR gamma
|
|
Concept
|
Receptor, Angiotensin, Type 1
|
|
Concept
|
Sodium-Glucose Transporter 2
|
|
Concept
|
Angiotensin II Type 1 Receptor Blockers
|
|
Concept
|
Endothelin-1
|
|
Concept
|
Fenoldopam
|
|
Concept
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
|
Concept
|
Perindopril
|
|
Concept
|
Aquaporins
|
|
Concept
|
Phenylpropionates
|
|
Concept
|
Piperidines
|
|
Concept
|
Isoprostanes
|
|
Concept
|
Propranolol
|
|
Concept
|
Propanolamines
|
|
Concept
|
Protein Kinase C
|
|
Concept
|
Pyrazoles
|
|
Concept
|
Pyrimidines
|
|
Concept
|
Quinazolines
|
|
Concept
|
Receptors, Dopamine
|
|
Concept
|
Pyrroles
|
|
Concept
|
Reagent Strips
|
|
Concept
|
Serum Albumin
|
|
Concept
|
Renin
|
|
Concept
|
RNA, Messenger
|
|
Concept
|
Sodium Chloride
|
|
Concept
|
Spironolactone
|
|
Concept
|
Sulfonamides
|
|
Concept
|
Thiazolidinediones
|
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
|
Concept
|
Cystatin C
|
|
Concept
|
Ubiquitin-Protein Ligases
|
|
Concept
|
Sodium Chloride Symporter Inhibitors
|
|
Concept
|
Sodium-Glucose Transport Proteins
|
|
Concept
|
Triazoles
|
|
Concept
|
Uracil
|
|
Concept
|
Steroids
|
|
Concept
|
Vitamin D
|
|
Concept
|
Thiazides
|
|
Concept
|
NF-E2-Related Factor 2
|
|
Concept
|
Cyclooxygenase 2
|
|
Concept
|
Thiazoles
|
|
Concept
|
Cyclosporine
|
|
Concept
|
Drug Monitoring
|
|
Concept
|
Adrenergic alpha-1 Receptor Antagonists
|
|
Concept
|
Adrenergic beta-1 Receptor Antagonists
|
|
Concept
|
Ramipril
|
|
Concept
|
Uromodulin
|
|
Concept
|
Receptors, Mineralocorticoid
|
|
Concept
|
Leuprolide
|
|
Concept
|
Troponin I
|
|
Concept
|
Dipeptidyl-Peptidase IV Inhibitors
|
|
Concept
|
Mibefradil
|
|
Concept
|
Nitric Oxide Synthase
|
|
Concept
|
Anti-Obesity Agents
|
|
Concept
|
Chemical and Drug Induced Liver Injury
|
|
Concept
|
Sodium Potassium Chloride Symporter Inhibitors
|
|
Concept
|
Organic Anion Transporters
|
|
Concept
|
Glucagon-Like Peptide 1
|
|
Concept
|
Lipocalins
|
|
Concept
|
Angiotensin Receptor Antagonists
|
|
Concept
|
Galectins
|
|
Concept
|
Vascular Endothelial Growth Factor A
|
|
Concept
|
Receptor, Endothelin A
|
|
Concept
|
Cytochrome P-450 CYP3A
|
|
Concept
|
Amides
|
|
Concept
|
Anti-Bacterial Agents
|
|
Concept
|
Hypolipidemic Agents
|
|
Concept
|
Antibodies, Antinuclear
|
|
Concept
|
Biguanides
|
|
Concept
|
Calcium
|
|
Concept
|
Calcium Channel Blockers
|
|
Concept
|
Cardiovascular Agents
|
|
Concept
|
Delayed-Action Preparations
|
|
Concept
|
Drug Eruptions
|
|
Concept
|
Diatrizoate
|
|
Concept
|
Diltiazem
|
|
Concept
|
Drug Administration Schedule
|
|
Concept
|
Epidermal Growth Factor
|
|
Concept
|
Gallium Radioisotopes
|
|
Concept
|
Glucose
|
|
Concept
|
Growth Substances
|
|
Concept
|
Ketone Bodies
|
|
Concept
|
Malondialdehyde
|
|
Concept
|
Naphthyridines
|
|
Concept
|
Niacinamide
|
|
Concept
|
Norepinephrine
|
|
Concept
|
Oleanolic Acid
|
|
Concept
|
Phosphates
|
|
Concept
|
Platelet Aggregation Inhibitors
|
|
Concept
|
Psychotropic Drugs
|
|
Concept
|
Receptors, Opioid
|
|
Concept
|
Theophylline
|
|
Concept
|
Zirconium
|
|
Concept
|
Cytokines
|
|
Concept
|
Endothelins
|
|
Concept
|
Oligonucleotides, Antisense
|
|
Concept
|
Misoprostol
|
|
Concept
|
Losartan
|
|
Concept
|
Nitric Oxide Donors
|
|
Concept
|
Calcium Channels, L-Type
|
|
Concept
|
Symporters
|
|
Concept
|
Peroxisome Proliferator-Activated Receptors
|
|
Concept
|
Adiponectin
|
|
Concept
|
Apoprotein(a)
|
|
Concept
|
Growth Differentiation Factor 15
|
|
Concept
|
Drug Substitution
|
|
Concept
|
Patient Safety
|
|
Concept
|
Insulin, Regular, Human
|
|
Academic Article
|
Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria.
|
|
Academic Article
|
Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy.
|
|
Academic Article
|
Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ?
|
|
Academic Article
|
Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy.
|
|
Academic Article
|
Renal mortality associated with non-insulin-dependent diabetes mellitus.
|
|
Academic Article
|
The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium.
|
|
Academic Article
|
Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients.
|
|
Academic Article
|
"Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives".
|
|
Academic Article
|
Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury.
|
|
Academic Article
|
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
|
|
Academic Article
|
Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study.
|
|
Academic Article
|
Diabetic hypertensive patients: improving their prognosis.
|
|
Academic Article
|
A practical approach to achieving recommended blood pressure goals in diabetic patients.
|
|
Academic Article
|
Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.
|
|
Academic Article
|
Hypertension in patients with diabetes. Strategies for drug therapy to reduce complications.
|
|
Academic Article
|
Oral antidiabetic agents safe with renal disease?
|
|
Academic Article
|
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
|
|
Academic Article
|
Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers.
|
|
Academic Article
|
The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.
|
|
Academic Article
|
Heart failure as a cause for hospitalization in chronic dialysis patients.
|
|
Academic Article
|
Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).
|
|
Academic Article
|
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.
|
|
Academic Article
|
Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker.
|
|
Academic Article
|
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
|
|
Academic Article
|
Achieving blood pressure goals: is fixed-dose combination therapy the answer?
|
|
Academic Article
|
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
|
|
Academic Article
|
How to adjust ACE inhibitors and ARBs in diabetes?
|
|
Academic Article
|
Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients?
|
|
Academic Article
|
Exfoliative dermatitis secondary to tobramycin sulfate.
|
|
Academic Article
|
George Bakris, MD: researching ways to combat hypertension. Interview by Mike Mitka.
|
|
Academic Article
|
The rationale and design of the AASK cohort study.
|
|
Academic Article
|
Preventing hypertensive kidney disease: the critical role of combination therapy.
|
|
Academic Article
|
Protecting renal function in the hypertensive patient: clinical guidelines.
|
|
Academic Article
|
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
|
|
Academic Article
|
Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?
|
|
Academic Article
|
Treatment of hypertension in patients with renal disease.
|
|
Academic Article
|
Clinical trials report. Combination drug treatment for hypertension with nondiabetic renal disease.
|
|
Academic Article
|
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.
|
|
Academic Article
|
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
|
|
Academic Article
|
Exceptional early blood pressure control rates: the ACCOMPLISH trial.
|
|
Academic Article
|
Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes.
|
|
Academic Article
|
Is ethnicity a factor in choice of antihypertensive drug?
|
|
Academic Article
|
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.
|
|
Academic Article
|
Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial.
|
|
Academic Article
|
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
|
|
Academic Article
|
The cardiometabolic syndrome and calcium channel blocker combination drugs.
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
|
|
Academic Article
|
Antihypertensive therapy in the presence of proteinuria.
|
|
Academic Article
|
Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker.
|
|
Academic Article
|
Who should be treated with combination therapy as initial treatment for hypertension?
|
|
Academic Article
|
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
|
|
Academic Article
|
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
|
|
Academic Article
|
Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
|
|
Academic Article
|
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
|
|
Academic Article
|
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
|
|
Academic Article
|
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.
|
|
Academic Article
|
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.
|
|
Academic Article
|
Newer combination therapies in the management of hypertension: an update.
|
|
Academic Article
|
Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study.
|
|
Academic Article
|
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
|
|
Academic Article
|
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study.
|
|
Academic Article
|
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.
|
|
Academic Article
|
Arginine vasopressin stimulates human mesangial cell production of endothelin.
|
|
Academic Article
|
Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium.
|
|
Academic Article
|
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
|
|
Academic Article
|
Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?
|
|
Academic Article
|
Resistant hypertension: an overview of evaluation and treatment.
|
|
Academic Article
|
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile.
|
|
Academic Article
|
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
|
|
Academic Article
|
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension.
|
|
Academic Article
|
Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?
|
|
Academic Article
|
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
|
|
Academic Article
|
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
|
|
Academic Article
|
Treatment and control of high blood pressure in adults.
|
|
Academic Article
|
24-hour ambulatory blood pressure in the ACCOMPLISH trial.
|
|
Academic Article
|
More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors.
|
|
Academic Article
|
Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies.
|
|
Academic Article
|
Importance of blood pressure control in left ventricular mass regression.
|
|
Academic Article
|
Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial.
|
|
Academic Article
|
Limitations of metformin use in patients with kidney disease: are they warranted?
|
|
Academic Article
|
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
|
|
Academic Article
|
Initial combination antihypertensives: let's ACCELERATE.
|
|
Academic Article
|
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
|
|
Academic Article
|
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
|
|
Academic Article
|
Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy.
|
|
Academic Article
|
Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.
|
|
Academic Article
|
Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
|
|
Academic Article
|
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.
|
|
Academic Article
|
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.
|
|
Academic Article
|
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study.
|
|
Academic Article
|
The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
|
|
Academic Article
|
Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
|
|
Academic Article
|
Assessment and management of vascular disease risk in patients with chronic kidney disease.
|
|
Academic Article
|
An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements.
|
|
Academic Article
|
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.
|
|
Academic Article
|
Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs.
|
|
Academic Article
|
Lithium prophylaxis and the kidney.
|
|
Academic Article
|
Chronic pain. A pharmacologic review and behavior modification approach.
|
|
Academic Article
|
Dermatologic manifestations of lithium: a review.
|
|
Academic Article
|
Are antihypertensive drugs associated with an increased risk of incident type 2 diabetes?
|
|
Academic Article
|
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
|
|
Academic Article
|
Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection.
|
|
Academic Article
|
Renal adaptation to the failing heart. Avoiding a 'therapeutic misadventure'.
|
|
Academic Article
|
Disopyramide-associated liver dysfunction.
|
|
Academic Article
|
Beta-blocker therapy in hypertension: a need to pause and reflect.
|
|
Academic Article
|
Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes.
|
|
Academic Article
|
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
|
|
Academic Article
|
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study.
|
|
Academic Article
|
Drug dosing in patients with renal insufficiency. A simplified approach.
|
|
Academic Article
|
Combination therapy in hypertension.
|
|
Academic Article
|
Fixed-dose combination and chronic kidney disease progression: which is the best?
|
|
Academic Article
|
Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy.
|
|
Academic Article
|
Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?
|
|
Academic Article
|
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
|
|
Academic Article
|
Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy.
|
|
Academic Article
|
Evolution of drugs that preserve renal function.
|
|
Academic Article
|
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
|
|
Academic Article
|
Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy.
|
|
Academic Article
|
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
|
|
Academic Article
|
Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension.
|
|
Academic Article
|
The future of blood pressure control in a population with a growing girth.
|
|
Academic Article
|
Dual RAAS blockade is desirable in kidney disease: con.
|
|
Academic Article
|
Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control.
|
|
Academic Article
|
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
|
|
Academic Article
|
Comparison of the effects of dopamine and fenoldopam, a selective dopamine-1 agonist, on parathyroid hormone release in man.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
|
|
Academic Article
|
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
|
|
Academic Article
|
Interventional cardiology: Indications for renal denervation: a balanced approach?
|
|
Academic Article
|
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.
|
|
Academic Article
|
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.
|
|
Academic Article
|
Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.
|
|
Academic Article
|
Efficacy of baroreflex activation therapy for the treatment of resistant hypertension.
|
|
Academic Article
|
Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus.
|
|
Academic Article
|
Initial single-pill combination therapy for cardiovascular risk factor management: it is not just convenience.
|
|
Academic Article
|
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
|
|
Academic Article
|
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
|
|
Academic Article
|
Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus.
|
|
Academic Article
|
Review of blood pressure control rates and outcomes.
|
|
Academic Article
|
Metformin nephrotoxicity insights: will they change clinical management?
|
|
Academic Article
|
CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
|
|
Academic Article
|
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
|
|
Academic Article
|
Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches.
|
|
Academic Article
|
The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension.
|
|
Academic Article
|
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension.
|
|
Academic Article
|
Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study.
|
|
Academic Article
|
Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
|
|
Academic Article
|
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension.
|
|
Academic Article
|
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|
|
Academic Article
|
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
|
|
Academic Article
|
Efficacy and safety of perindopril arginine + amlodipine in hypertension.
|
|
Academic Article
|
Sympathetic activation in resistant hypertension: theory and therapy.
|
|
Academic Article
|
Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013.
|
|
Academic Article
|
Renal denervation for resistant hypertension and beyond.
|
|
Academic Article
|
4A.10: PREFERENTIAL REDUCTION IN MORNING/NOCTURNAL HYPERTENSION BY RENAL DENERVATION FOR DRUG- RESISTANT HYPERTENSION: A NEW ABPM ANALYSIS OF SYMPLICITY HTN-3 AND HTN-JAPAN.
|
|
Academic Article
|
Renal Denervation After SYMPLICITY HTN-3: Where Do We Go?
|
|
Academic Article
|
Summary and Conclusions.
|
|
Academic Article
|
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
|
|
Academic Article
|
Renal denervation for the treatment of resistant hypertension: review and clinical perspective.
|
|
Academic Article
|
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial.
|
|
Academic Article
|
Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension.
|
|
Academic Article
|
Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.
|
|
Academic Article
|
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
|
|
Academic Article
|
Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
|
|
Academic Article
|
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy.
|
|
Academic Article
|
Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial.
|
|
Academic Article
|
From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century.
|
|
Academic Article
|
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
|
|
Academic Article
|
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.
|
|
Academic Article
|
New Onset Hypertension Linked to Generic Cyclosporine Substitution in Post-Renal Transplant Patient.
|
|
Academic Article
|
Mineralocorticoid antagonists in chronic kidney disease.
|
|
Academic Article
|
Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"?
|
|
Academic Article
|
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.
|
|
Academic Article
|
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
|
|
Academic Article
|
Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease.
|
|
Academic Article
|
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
|
|
Academic Article
|
Baseline characteristics and enrichment results from the SONAR trial.
|
|
Academic Article
|
A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.
|
|
Academic Article
|
Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment.
|
|
Academic Article
|
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
|
|
Academic Article
|
Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status.
|
|
Academic Article
|
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
|
|
Academic Article
|
Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.
|
|
Academic Article
|
Initial single-pill combinations for antihypertensive treatment: greater cardiovascular mortality reduction yet still not used.
|
|
Academic Article
|
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
|
|
Academic Article
|
MY APPROACH to the elderly patient with resistant hypertension.
|
|
Academic Article
|
Drug dosing in patients with renal insufficiency.
|
|
Academic Article
|
Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study.
|
|
Academic Article
|
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
|
|
Academic Article
|
Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
|
|
Academic Article
|
Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension.
|
|
Academic Article
|
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
|
|
Academic Article
|
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
|
|
Academic Article
|
Optimizing Blood Pressure Control Without Adding Anti-Hypertensive Medications.
|
|
Academic Article
|
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
|
|
Academic Article
|
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
|
|
Academic Article
|
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension.
|
|
Academic Article
|
Initial Drops in Glomerular Filtration Rate with Certain Drug Classes Retard Kidney Disease Progression.
|
|
Academic Article
|
Novel antihypertensive agents for resistant hypertension: what does the future hold?
|
|
Concept
|
Contraindications, Drug
|
|
Concept
|
Drug-Related Side Effects and Adverse Reactions
|
|
Concept
|
Protein Kinase C beta
|
|
Concept
|
Glycoside Hydrolase Inhibitors
|
|
Concept
|
Antidiuretic Hormone Receptor Antagonists
|
|
Concept
|
Endothelin A Receptor Antagonists
|
|
Concept
|
Endothelin Receptor Antagonists
|
|
Academic Article
|
Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study.
|